203 related articles for article (PubMed ID: 29858134)
1. [Prostate brachytherapy: New techniques, new indications].
Blanchard P; Graff-Cailleaud P; Bossi A
Cancer Radiother; 2018 Jun; 22(4):352-358. PubMed ID: 29858134
[TBL] [Abstract][Full Text] [Related]
2. [Which modality for prostate brachytherapy?].
Bossi A
Cancer Radiother; 2010 Oct; 14(6-7):488-92. PubMed ID: 20724190
[TBL] [Abstract][Full Text] [Related]
3. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
4. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of prostate cancer brachytherapy].
Hannoun-Levi JM; Chevallier D; Cosset JM; Gerbaulet A
Bull Cancer; 2012 Dec; 99(12):1175-81. PubMed ID: 23228827
[TBL] [Abstract][Full Text] [Related]
6. [Brachytherapy for prostate carcinoma].
Yorozu A
Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr; 65(2):87-91. PubMed ID: 15920966
[TBL] [Abstract][Full Text] [Related]
7. Brachytherapy for prostate cancer: Present and future.
Hannoun-Lévi JM
Cancer Radiother; 2017 Oct; 21(6-7):469-472. PubMed ID: 28847460
[TBL] [Abstract][Full Text] [Related]
8. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
9. The role of brachytherapy in the definitive management of prostate cancer.
Crook J
Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
[TBL] [Abstract][Full Text] [Related]
10. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
11. Permanent prostate brachytherapy: lessons learned, lessons to learn.
Potters L
Oncology (Williston Park); 2000 Jul; 14(7):981-91; discussion 991-2, 997-9. PubMed ID: 10929587
[TBL] [Abstract][Full Text] [Related]
12. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
13. [Brachytherapy for prostate cancer: old concept, new techniques].
Cosset JM; Flam T; Thiounn N; Rosenwald JC; Pontvert D; Timbert M; Solignac S; Chauveinc L
Bull Cancer; 2006 Aug; 93(8):761-6. PubMed ID: 16935780
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
15. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
16. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
17. Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature.
Gaztañaga M; Crook JM
Brachytherapy; 2013; 12(4):338-42. PubMed ID: 22748289
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
19. [Prostate cancer brachytherapy].
Pommier P; Guérif S; Peiffert D; Créhange G; Hannoun-Lévi JM; de Crevoisier R
Cancer Radiother; 2016 Sep; 20 Suppl():S210-5. PubMed ID: 27523412
[TBL] [Abstract][Full Text] [Related]
20. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
